<?xml version="1.0"?>
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HCF7AE08ABAE540D0B3B26D48F68627C0" public-private="public">
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>110 HR 1902 IH: To prohibit brand name drug companies from compensating
</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2007-04-17</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
	<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>110th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 1902</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20070417">April 17, 2007</action-date>
			<action-desc><sponsor name-id="R000515">Mr. Rush</sponsor> (for
			 himself, <cosponsor name-id="W000215">Mr. Waxman</cosponsor>,
			 <cosponsor name-id="M000133">Mr. Markey</cosponsor>,
			 <cosponsor name-id="B001251">Mr. Butterfield</cosponsor>,
			 <cosponsor name-id="D000482">Mr. Doyle</cosponsor>,
			 <cosponsor name-id="S001145">Ms. Schakowsky</cosponsor>, and
			 <cosponsor name-id="D000355">Mr. Dingell</cosponsor>) introduced the following
			 bill; which was referred to the <committee-name committee-id="HIF00">Committee
			 on Energy and Commerce</committee-name>, and in addition to the Committee on
			 the <committee-name committee-id="HJU00">Judiciary</committee-name>, for a
			 period to be subsequently determined by the Speaker, in each case for
			 consideration of such provisions as fall within the jurisdiction of the
			 committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To prohibit brand name drug companies from compensating
		  generic drug companies to delay the entry of a generic drug into the market,
		  and for other purposes.</official-title>
	</form>
	<legis-body id="HBC06DF84BA944BE6B15BB773C92FA841" style="OLC">
		<section display-inline="no-display-inline" id="HBBAC08B2539144F89CFF92B70042E57D" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the
			 <quote>Protecting Consumer Access to Generic Drugs Act of 2007</quote>.</text>
		</section><section id="H5437532AD95F441A8D2BE2BC886FE1ED"><enum>2.</enum><header>Unfair and
			 deceptive acts and practices related to new drug applications</header>
			<subsection id="H2CE467F9168247C68607386CCA0132EC"><enum>(a)</enum><header>Conduct
			 prohibited</header><text display-inline="yes-display-inline">It shall be
			 unlawful for any person to directly or indirectly be a party to any agreement
			 resolving or settling a patent infringement claim in which—</text>
				<paragraph id="HB8391E7997074462A6246F0026613000"><enum>(1)</enum><text>an ANDA filer
			 receives anything of value; and</text>
				</paragraph><paragraph id="HCB3C430DDE794D239EA5E2412D2F49ED"><enum>(2)</enum><text>the ANDA filer
			 agrees not to research, develop, manufacture, market, or sell, for any period
			 of time, the drug that is to be manufactured under the ANDA involved and is the
			 subject of the patent infringement claim.</text>
				</paragraph></subsection><subsection commented="no" id="H16CAB48FC6BF459E8600F2C254ABA500"><enum>(b)</enum><header>Exceptions</header><text display-inline="yes-display-inline">Notwithstanding subsection (a)(1),
			 subsection (a) does not prohibit a resolution or settlement of a patent
			 infringement claim in which the value received by the ANDA filer includes no
			 more than—</text>
				<paragraph id="H79C0D34B87B54961B5ED8F9DE8ED60CD"><enum>(1)</enum><text display-inline="yes-display-inline">the right to market the drug that is to be
			 manufactured under the ANDA involved and is the subject of the patent
			 infringement claim, before the expiration of—</text>
					<subparagraph id="H57143AAB372445F8831DA4F7DDB132D"><enum>(A)</enum><text>the patent that is
			 the basis for the patent infringement claim; or</text>
					</subparagraph><subparagraph id="H7B3795250C43413F8E5FA2324C664EFF"><enum>(B)</enum><text>any other
			 statutory exclusivity that would prevent the marketing of such drug; and</text>
					</subparagraph></paragraph><paragraph id="H20C11A22943A418E887B6BA9DF7DFC48"><enum>(2)</enum><text>the waiver of a
			 patent infringement claim for damages based on prior marketing of such
			 drug.</text>
				</paragraph></subsection><subsection id="HD33E0BA3886E43FAA7B20026EDE93489"><enum>(c)</enum><header>Enforcement</header><text>A
			 violation of subsection (a) shall be treated as an unfair and deceptive act or
			 practice and an unfair method of competition in or affecting interstate
			 commerce prohibited under section 5 of the Federal Trade Commission Act (15
			 U.S.C. 45). The Federal Trade Commission shall enforce this Act in the same
			 manner, by the same means, and with the same jurisdiction as though all
			 applicable terms and provisions of the Federal Trade Commission Act were
			 incorporated into and made a part of this Act.</text>
			</subsection><subsection id="H3A424CF7EF8F46D5B544F767DF5300F8"><enum>(d)</enum><header>Definitions</header><text>In this section:</text>
				<paragraph commented="no" id="H4A8F890318A34D2B9CF6C40843001200"><enum>(1)</enum><header>Agreement</header><text>The
			 term <term>agreement</term> means anything that would constitute an agreement
			 for purposes of section 5 of the Federal Trade Commission Act (15 U.S.C.
			 45).</text>
				</paragraph><paragraph commented="no" id="H66BC6A212D7A499593001183B70817F7"><enum>(2)</enum><header>Agreement
			 resolving or settling</header><text>The term <term>agreement resolving or
			 settling</term>, in reference to a patent infringement claim, includes any
			 agreement that is contingent upon, provides a contingent condition for, or is
			 otherwise related to the resolution or settlement of the claim.</text>
				</paragraph><paragraph id="H1CDE4CBA64684BB695DBF461FB941B8B"><enum>(3)</enum><header>ANDA</header><text>The
			 term <term>ANDA</term> means an abbreviated new drug application for the
			 approval of a new drug under section 505(j) of the Federal Food, Drug, and
			 Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>).</text>
				</paragraph><paragraph id="H4D01FB2F8F5D4E05BE002C6E9517EBDB"><enum>(4)</enum><header>ANDA
			 filer</header><text display-inline="yes-display-inline">The term <term>ANDA
			 filer</term> means a party that has filed an ANDA with the Food and Drug
			 Administration.</text>
				</paragraph><paragraph commented="no" id="H994446731F744B91B5FAAEAE3EC400B5"><enum>(5)</enum><header>Patent
			 infringement</header><text>The term <term>patent infringement</term> means
			 infringement of any patent or of any filed patent application, extension,
			 reissuance, renewal, division, continuation, continuation in part,
			 reexamination, patent term restoration, patent of addition, or extension
			 thereof.</text>
				</paragraph><paragraph commented="no" id="HD79B4D0D9FC041F689CE46247DDFB0D7"><enum>(6)</enum><header>Patent
			 infringement claim</header><text>The term <term>patent infringement
			 claim</term> means any allegation made to an ANDA filer, whether or not
			 included in a complaint filed with a court of law, that its ANDA or drug to be
			 manufactured under such ANDA may infringe any patent.</text>
				</paragraph></subsection></section><section id="HD30F64683D134BAF80544620FE66E533"><enum>3.</enum><header>FTC
			 Rulemaking</header><text display-inline="no-display-inline">The Federal Trade
			 Commission may, by rule promulgated under <external-xref legal-doc="usc" parsable-cite="usc/5/553">section 553</external-xref> of title 5, United States
			 Code, exempt certain agreements described in section 2 if the Commission finds
			 such agreements to be in furtherance of market competition and for the benefit
			 of consumers. Consistent with the authority of the Commission, such rules may
			 include interpretive rules and general statements of policy with respect to the
			 practices prohibited under section 2.</text>
		</section><section commented="no" id="H94B375423CDE4823B316F6C644CC29F6"><enum>4.</enum><header>Forfeiture of
			 180-day exclusivity period under the FFDCA</header><text display-inline="no-display-inline">Section 505(j)(5)(D)(i) of the Federal Food,
			 Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(5)(D)(i)</external-xref>) is amended—</text>
			<paragraph commented="no" id="H60E0AA4E5A6B48A185C1236EE5E1E13"><enum>(1)</enum><text>in subclause
			 (I)(bb)—</text>
				<subparagraph commented="no" id="HC52A3E40B1544A609982F3E672FC8844"><enum>(A)</enum><text>by redesignating
			 subitem (CC) as subitem (EE); and</text>
				</subparagraph><subparagraph commented="no" id="H99A6CD1FA5E648C2A5CD5F863D2E068C"><enum>(B)</enum><text>by inserting after
			 subitem (BB) the following:</text>
					<quoted-block display-inline="no-display-inline" id="HEAFB61DAEB7D4F18B6654BF5E63783B0" style="OLC">
						<subitem commented="no" id="HD227A07733F84E14AEFA12CF296E8FD"><enum>(CC)</enum><text display-inline="yes-display-inline">In a declaratory judgment action described
				in subitem (AA), a court dismisses the action for lack of subject matter
				jurisdiction, either with or without prejudice.</text>
						</subitem><subitem commented="no" id="HF928260CDD5F456787E46F5DE241A6D3"><enum>(DD)</enum><text>The applicant
				files with the Secretary a covenant by the patent owner that the patent owner
				will not sue the applicant for infringement with respect to the
				patent.</text>
						</subitem><after-quoted-block>;
				and</after-quoted-block></quoted-block>
				</subparagraph></paragraph><paragraph commented="no" id="H75036BC274464984A80067A89D7800CB"><enum>(2)</enum><text display-inline="yes-display-inline">in subclause (V), by inserting
			 <quote>section 2 of the Protecting Consumer Access to Generic Drugs Act of 2007
			 or</quote> after <quote>that the agreement has violated</quote>.</text>
			</paragraph></section><section display-inline="no-display-inline" id="HD146C72A01B3421CAF6FCF7E99B3FEC4" section-type="subsequent-section"><enum>5.</enum><header>Notice and
			 certification of agreements</header>
			<subsection id="H0869306F09C04D588FE56EF86E7444FD"><enum>(a)</enum><header>Notice of all
			 agreements</header><text>Section 1112(c)(2) of the Medicare Prescription Drug,
			 Improvement, and Modernization Act of 2003 (<external-xref legal-doc="usc" parsable-cite="usc/21/3155">21 U.S.C. 3155</external-xref> note) is amended
			 by—</text>
				<paragraph id="HC1E471E5305740B08D77EEA83F3F2BC7"><enum>(1)</enum><text>striking
			 <quote>the Commission the</quote> and inserting <quote>the Commission (1)
			 the</quote>; and</text>
				</paragraph><paragraph id="HE98FD8376B044F7EB267F0066B315254"><enum>(2)</enum><text>inserting before
			 the period at the end the following: <quote>; and (2) a description of the
			 subject matter of any other agreement the parties enter into within 30 days of
			 an entering into an agreement covered by subsection (a) or (b)</quote>.</text>
				</paragraph></subsection><subsection id="H2A46513F296E481E910743A4F8FD6F74"><enum>(b)</enum><header>Certification of
			 agreements</header><text>Section 1112 of such Act is amended by adding at the
			 end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H1B839E5AFE054624A39000A8D11CC00" style="OLC">
					<subsection id="HD6CB351A9AB94C7FB72929B18300F8E3"><enum>(d)</enum><header>Certification</header><text>The
				Chief Executive Officer or the company official responsible for negotiating any
				agreement required to be filed under subsection (a), (b), or (c) shall execute
				and file with the Assistant Attorney General and the Commission a certification
				as follows: <quote>I declare under penalty of perjury that the following is
				true and correct: The materials filed with the Federal Trade Commission and the
				Department of Justice under section 1112 of subtitle B of title XI of the
				Medicare Prescription Drug, Improvement, and Modernization Act of 2003, with
				respect to the agreement referenced in this certification: (1) represent the
				complete, final, and exclusive agreement between the parties; (2) include any
				ancillary agreements that are contingent upon, provide a contingent condition
				for, or are otherwise related to, the referenced agreement; and (3) include
				written descriptions of any oral agreements, representations, commitments, or
				promises between the parties that are responsive to subsection (a) or (b) of
				such section 1112 and have not been reduced to
				writing.</quote>.</text>
					</subsection><after-quoted-block>.</after-quoted-block></quoted-block>
			</subsection></section></legis-body>
</bill>


